Skip to content
drillr.ai
Sign up

02256.HK

Abbisko Cayman Limited

HKSE · Healthcare · Biotechnology · CN

HKD 8.77
−1.79%
Ask drillr

  • Aug 24, 2026, 18:06 UTC

    Abbisko Therapeutics reported an interim net loss of 193 million RMB for the six months ended June 2026, swinging from a profit of 328 million RMB a year earlier, with revenue down 84.1% to 97.27 million RMB.

    Source:

  • Jun 24, 2026, 01:38 UTC

    Abbisko Therapeutics entered into a strategic research collaboration and license agreement with Eli Lilly.

    Source: